Particle.news

Download on the App Store

FDA Approves First Standalone Nasal Spray for Treatment-Resistant Depression

Spravato, derived from ketamine, offers rapid relief for severe depression and is available only under medical supervision.

Image
An estimated 21 million American adults suffer from clinical depression.
Woman holds signs depicting smiley and sad faces.

Overview

  • Spravato, a nasal spray developed by Johnson & Johnson, is the first FDA-approved standalone therapy for treatment-resistant depression.
  • The drug, derived from esketamine, targets the neurotransmitter glutamate and can reduce depressive symptoms in as little as 24 hours.
  • Previously approved in 2019 as an add-on therapy, Spravato's expanded approval is based on a study showing significant improvements compared to a placebo.
  • Due to potential side effects, including sedation and dissociation, the treatment is only available through certified centers under strict medical supervision.
  • This approval provides a new option for the estimated one-third of U.S. adults with major depressive disorder who do not respond to traditional antidepressants.